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Background: Restorative proctocolectomy with ileal pouch–anal anastomosis (IPAA) has become the standard surgical treatment for the majority of
patients with inflammatory bowel disease (IBD) who require colectomy. We evaluated the prevalence of pouch-related symptoms among the Crohn’s and
Colitis Foundation of America Partners cohort and the effect of pouch-related symptoms on Patient-Reported Outcome Measurement Information System
measures.
Methods: We performed analyses nested in the Crohn’s and Colitis Foundation of America Partners cohort. We used bivariate analyses to compare
demographics and medication use among patients with ulcerative colitis or indeterminate colitis and pouch-related symptoms and those with IPAA
without symptoms. We also compared Patient-Reported Outcome Measurement Information System domains (measured in T-scores) and short IBD
questionnaire quality of life scales between symptomatic pouch patients (over the past 6 mo) and those without symptoms.
Results: Among 243 patients reporting a history of IPAA, 199 (82%) reported a history of pouch symptoms. Patients with recent pouch symptoms
demonstrated higher mean T-scores in pain interference (53.0 versus 45.3; P, 0.001), depression (51.0 versus 46.4; P ¼ 0.002), and fatigue (56.3 versus
47.0; P , 0.001). Symptomatic pouch patients reported lower mean scores in social role satisfaction (47.4 versus 54.6) and short IBD questionnaire (4.8
versus 5.8) (both P , 0.001). These differences were all clinically meaningful.
Conclusions: In a large sample of patients with IBD, nearly all patients with IPAA reported a history of pouch symptoms. Patients experiencing
symptoms within the 6 months before the survey assessment demonstrated clinically meaningful decrements in patient-reported outcomes in multiple
domains of physical and psychosocial functioning.
(Inflamm Bowel Dis 2017;23:1218–1224)
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A pproximately 20% to 35% of patients with ulcerative colitis(UC) eventually will require colectomy due to refractory dis-
ease or histologically proven dysplasia.1–3 Given the ability to
accomplish the major goals of eliminating the diseased segment
of intestine while maintaining fecal continence, restorative proc-
tocolectomy with ileal pouch–anal anastomosis (IPAA) has
become the standard surgical treatment for the majority of patients
who require colectomy. Additionally, the pouch procedure has
been shown to significantly improve the health-related quality of
life (QOL) of patients while reducing the risk for colitis-
associated neoplasia.4
There are known complications that can occur after IPAA
surgery. Among the potential complications, pouchitis is the
most common long-term complication after IPAA, affecting
50% to 79% of patients after IPAA for UC.1,5–13 Several risk
factors for pouchitis have been suggested in previous studies,
including extensive UC,14,15 a concurrent diagnosis of primary
sclerosing cholangitis,16–18 backwash ileitis,18,19 nonsmoking
status,14,15 the regular use of nonsteroidal anti-inflammatory
drugs,14,17 and ischemia.20
The majority of the studies that have evaluated pouchitis
and pouch-related impact thus far have been performed in single-
center cohorts. However, as clinical outcomes may vary
depending on the center where pouch procedures are performed,2
a broader understanding of pouchitis and the effect of pouch-
related symptoms on related clinical outcomes is needed. The
primary objective of our study was to use the Crohn’s and Colitis
Foundation of America (CCFA) Partners infrastructure to evaluate
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the prevalence of pouch-related symptoms and the impact of
pouch-related symptoms on patient-reported outcomes (PROs) in
participants with a history of IPAA. We used the Patient-Reported
Outcomes Measurement Information System (PROMIS) measures
including anxiety, depression, sleep disturbances, fatigue, pain
interference, and social satisfaction to compare symptomatic pouch
patients with those without pouch-related symptoms.
METHODS
Study Population
We identified patients with a history of IPAA within CCFA
Partners, an Internet-based cohort of patients with inflammatory
bowel disease (IBD). The study cohort has been described in
detail previously.21 Briefly, patients were recruited to enroll in this
online cohort registry through a variety of means, including in-
vitations by means of e-mail, social media, and recruitment at
CCFA educational events. More than 15,000 patients with self-
reported IBD have enrolled in the cohort since its initiation in
2011, and cohort members are followed up at 6-month intervals.
Baseline and follow-up surveys include a core survey with infor-
mation on disease phenotype, activity, medication use, and PROs.
Optional “modules” can also be completed alongside the core
survey at 6-month intervals to assess specific areas of interest
among patients with IBD, including pouch-related complications
and QOL.
For inclusion in this study, patients needed to be older than
18 years, diagnosed with UC or indeterminate colitis (IC), and
with a history of colectomy with IPAA. Patients with a diagnosis
of Crohn’s disease were excluded from this study. There were no
other exclusion criteria.
Study Variables
All patients completed questionnaires regarding demo-
graphic and clinical information, in addition to validated scales
including the short IBD questionnaire (SIBDQ),22 and the
PROMIS measures for pain interference, anxiety, depression, sat-
isfaction with social role, sleep disturbance, and fatigue.23,24 The
SIBDQ has not specifically been validated in pouch populations;
however, the instrument includes domains with clinical relevance
to this IBD subpopulation, including bowel symptoms, systemic
symptoms, emotional function, and social function and has been
used in the evaluation of patients with Crohn’s disease pheno-
types of the pouch.25
In addition to the survey measures described above,
patients were questioned regarding any history of symptoms
of pouchitis, including abdominal pain, cramping, and urgent or
frequent bowel movements and then separately regarding
a history of pouch-related symptoms within the preceding 6
months. If a patient completed multiple surveys within the study
period, all survey responses were analyzed for a positive history
of pouch-related symptoms at any point. If a patient answered
positively to the question regarding pouch-related symptoms in
the preceding 6 months on multiple surveys, then the first
survey where pouch-related symptoms were reported was
analyzed for the evaluation of PROMIS measures. If a patient
completed multiple surveys and never experienced pouch-
related symptoms, then the last survey completed was analyzed
for the evaluation of PROMIS measures. This method was
chosen to allow for more complete capture of patients without
pouch-related symptoms because the question regarding pouch-
related symptoms in the preceding 6 months may not have been
available in the baseline survey depending on how long an
individual had participated in CCFA Partners.
The PROMIS measures have previously been assessed
within the CCFA Partners cohort24 and have been validated in
other general and chronically ill populations for the self-reporting
of outcomes.26,27 PROMIS measures are calibrated using T-score
metrics to provide mean values for each domain, with higher
scores indicating higher levels of each domain being measured.
Among generally healthy populations, the mean T-score for pain
interference, depression, anxiety, satisfaction with one’s social
role, fatigue, and sleep disturbance is 50 with a standard deviation
of 10. Based on previous studies evaluating the PROMIS meas-
ures in patients with IBD and other chronic conditions such as
rheumatoid arthritis,24,28–31 a minimally important difference of 2
was assigned when analyzing PROMIS measures.
Statistical Analysis
Baseline demographics and clinical characteristics were
compared using proportions and 95% confidence intervals (CI),
means with standard deviation, and medians with interquartile
ranges as appropriate. Bivariate statistics using Pearson’s chi-
square test statistic, Fisher’s exact, Wilcoxon’s rank sum, and
Student’s t test as appropriate were used to compare symptom-
atic pouch patients with those with no reported history of symp-
toms. Logistic regression modeling was used to compare the
effect of pouch-related symptoms within the prior 6 months
on individual PROs as assessed by the PROMIS measures, after
controlling for covariates. When using logistic regression,
the minimally important difference of 2 in each PRO scale
was used as the threshold for assessment. Categorical variables
for each PROMIS domain were created using a threshold of
.52 for pain interference, depression, anxiety, fatigue, and
sleep disturbance and a threshold of ,48 for satisfaction with
social role. In multivariable analyses, an a priori decision was
made to include age and sex in all models, given the potential
for confounding. All statistical analyses were performed using
SAS statistical software (version 9.4; SAS Institute, Cary, NC).
The Institutional Review Board at the University of North
Carolina at Chapel Hill approved the study protocol.
RESULTS
A total of 243 participants in CCFA Partners reported
a history of colectomy with IPAA. Of these, 199 (82%) reported
a history of pouch-related symptoms on at least 1 survey at any
time in the interval following their initial IPAA surgery. There
were no significant differences in age, sex, or race when
comparing symptomatic pouch patients with those without
a history of pouch-related symptoms (Table 1). Significant differ-
ences were noted when analyzing the number of years since the
diagnosis of IBD (P ¼ 0.034), with 89% of patients with colitis
for more than 11 years reporting at least 1 episode of pouch-
related symptoms (Table 1). At each time point analyzed, a greater
percentage of patients reported at least 1 episode of pouch-related
symptoms when compared with those with a pouch who had not
experienced symptoms (Fig. 1).
Symptomatic pouch patients were more likely to report the
use of antibiotics (30% versus 0; P, 0.001) and aminosalicylates
(10% versus 0; P ¼ 0.030) when compared with asymptomatic
patients. No significant differences were noted in the use of pro-
biotics, narcotic pain medications, oral steroids, biologic agents,
or immunosuppressive therapies (Table 1). There was no signif-
icant difference in practice setting when comparing symptomatic
pouch patients with those without symptoms; however, a minority
of patients in both the groups reported being treated at a university
hospital (Table 1).
When examining PROMIS measures, a total of 222 patients
(91%) completed questionnaires regarding PROMIS and QOL
measures. Of these, 187 (84%) reported pouch-related symptoms
in the preceding 6 months. Symptomatic pouch patients demon-
strated greater pain interference, depression, fatigue, and less
satisfaction with their social role (Table 2). All of these differ-
ences were both statistically significant and clinically meaningful,
as defined by the prespecified minimally important difference.
Additionally, patients with symptoms in the preceding 6 months
reported decreased QOL as defined by the SIBDQ when com-
pared with those without pouch-related symptoms (mean SIBDQ,
4.8 versus 5.8; P , 0.001).
Using multivariable logistic regression to evaluate the
independent association between pouch-related symptoms within
the preceding 6 months on PROs, several significant associations
were demonstrated. In both unadjusted analysis and adjusted
analyses, symptomatic pouch patients demonstrated worse out-
comes on several PROs as defined by PROMIS measures
(Table 3). After adjusting for age and sex, symptomatic pouch
patients in the preceding 6 months demonstrated greater pain
interference (adjusted odds ratio, 3.99; 95% confidence interval,
1.53–10.41) and fatigue (adjusted odds ratio, 4.52; 95% confi-
dence interval, 2.88–10.90). Patients with pouch-related symp-
toms in the preceding 6 months also reported decreased
satisfaction with their social role (adjusted odds ratio, 0.24;
95% confidence interval, 0.09–0.63).
DISCUSSION
In an analysis of a large, geographically diverse cohort of
patients with UC or IC reporting a history of proctocolectomy
with IPAA for IBD, we evaluated the prevalence of patient-
reported pouchitis symptoms, which is the most common long-
term complication associated with IPAA. Our population was
treated in multiple practice settings, with a majority of symptom-
atic pouch patients being treated in a community-based practice.
We demonstrated that pouch-related symptoms occur frequently
in patients who undergo restorative proctocolectomy with IPAA
for IBD-related reasons and that antibiotics and probiotics seem to
be the most frequently used therapy. Symptomatic pouch patients
TABLE 1. Comparison of Demographics and Clinical
Characteristics Among Patients from CCFA Partners









18–39 21 (48%) 109 (55%)
40–59 19 (43%) 74 (37%)
.60 4 (9%) 16 (8%)
Female 27 (61%) 141 (71%)
Race
White 38 (86%) 182 (91%)
Black 0 3 (2%)
Other/not reported 6 (13%) 14 (8%)
Current smoker 0 5 (3%)
Time since IBD diagnosis, yr
,1 3 (7%) 9 (5%)
1–5 17 (39%) 39 (20%)
6–10 11 (25%) 46 (23%)
11–15 4 (9%) 43 (22%)
.15 9 (20%) 62 (31%)
Current therapy
Antibiotics 0 60 (30%)
Probiotics 10 (23%) 72 (36%)
Oral steroids 1 (2%) 14 (7%)
Aminosalicylates 0 20 (10%)
Biologic therapy 0 11 (6%)
Immunosuppressive therapy 0 7 (4%)
Narcotic pain medications 5 (11%) 29 (15%)
Current gastroenterology
provider setting
n ¼ 30 n ¼ 162
University hospital 9 (30%) 46 (28%)
Community practice 15 (50%) 100 (62%)
Other/don’t know setting 6 (20%) 16 (10%)
Number of times
a gastroenterologist has been
seen in the past year
n ¼ 30 n ¼ 162
None 7 (23%) 24 (15%)
1 or 2 times 15 (50%) 82 (51%)
3 or 4 times 4 (13%) 24 (15%)
5 or more times 4 (13%) 32 (20%)
with symptoms in the previous 6 months demonstrated worse
PROs as defined by PROMIS measures, including increased pain
interference, depression, and fatigue, as well as decreased
satisfaction with the social role and decreased QOL as defined
by the SIBDQ.
The frequency of reported pouch-related symptoms after
colectomy of 82% in our cohort study is higher than previously
assessed in most of the single-center studies.1,5–8 The higher inci-
dence of pouch-related symptoms could be due to the variable
window of assessment of pouchitis symptoms used in our surveys
compared with other studies. Another potential explanation is that
patients are also treated for pouch-related symptoms by their pri-
mary care providers and thus do not always report their symptoms
to the center that performed the colectomy with IPAA. Addition-
ally, we were unable to verify a diagnosis of self-reported pou-
chitis symptoms by means of endoscopy or review of the medical
record.
Gut microbiota may be involved in the pathogenesis of
pouchitis through multiple mechanisms, including an alteration
in commensal bacteria.32–35 This focus on the microbiota was
reflected in medication use patterns of the patients in our study
because a significantly greater number of symptomatic pouch
patients reported current use of antibiotics as compared with
those with no history of pouch-related symptoms. A greater
number of patients with pouch-related symptoms also reported
the use of probiotics, although this result was not statistically
significant. Although antibiotics such as ciprofloxacin or met-
ronidazole are viewed as the first-line therapy for acute
pouchitis,4,36–38 our findings confirm that among a diverse sur-
vey of patients with IPAA, antibiotics and probiotics are being
used more widely among symptomatic pouch patients than anti-
inflammatory medications such as steroids, biologic therapy, or
other immunosuppressive agents. Interestingly, 11% of patients
were also treated with aminosalicylate for pouch-related symp-
toms, which has only proven to be effective for the local treat-
ment of cuffitis but not pouchitis.39,40
Classically, the majority of pouch surgeries have been
performed in young patients with long life expectancies following
colectomy with IPAA. As patients age, the risk of developing
pouchitis increases,41 a finding that was suggested in our study.
Our survey did not specifically ask the date of colectomy or
ileostomy, and thus we were unable to analyze the time since
the last surgery related to the IPAA. In prior longitudinal
FIGURE 1. The percentage of patients with and without pouch-related symptoms compared with the number of years since diagnosis of UC/IC.
TABLE 2. Comparison of PROMIS and QOL Measures
Among Patients from CCFA Partners with a History of
Pouch-Related Symptoms Within 6 Months of Survey












(n ¼ 187) P
Pain interference 45.3 (6.4) 53.0 (10.9) ,0.001
Depression 46.4 (7.1) 51.0 (9.5) 0.002
Anxiety 48.8 (7.4) 51.9 (9.7) 0.075
Satisfaction with social
role
54.6 (7.6) 47.4 (9.8) ,0.001
Fatigue 47.0 (8.2) 56.3 (10.5) ,0.001
Sleep disturbance 51.9 (3.6) 51.8 (3.8) 0.854
SIBDQ 5.8 (0.9) 4.8 (1.2) ,0.001
Scores reported as mean (standard deviation).
a pouch who were symptomatic within the preceding 6 months
demonstrated clinically meaningful worsened outcomes in
several areas assessed by PROMIS measures, including pain
interference, depression, satisfaction with social role, and
fatigue when compared with those without pouch-related
symptoms. However, even symptomatic pouch patients dem-
onstrated PROMIS T-scores within 1 standard deviation of 50,
indicating that although pouch-related symptoms were asso-
ciated with worse outcomes in several domains of QOL, these
may not be as significant as in other chronic diseases.54,55
These findings may be particularly helpful when discussing
potential outcomes in the preoperative period while patients
are considering colectomy. Additionally, those patients with-
out pouch-related symptoms demonstrated PROMIS T-scores
that were better than the mean scores of the general population
in multiple domains.
Our study is the first to use the PROMIS measures to
evaluate PROs among patients with IBD who have undergone
proctocolectomy with IPAA. The PROMIS initiative of the
National Institutes of Health was developed to advance the
application of PROs in research and clinical practice.23
Although other studies have evaluated QOL among patients
with a history of IPAA, we believe that the use of the PROMIS
measures in a geographically diverse sample is a strength of this
study.
The majority of the prior studies that have evaluated
pouchitis have largely been limited to single-center reports.
Although these studies have significantly increased our under-
standing of the risk factors associated with the development of
pouchitis among patients undergoing IPAA and the epidemiol-
ogy of pouchitis among patients with IBD undergoing restor-
ative proctocolectomy with IPAA, the fact that these cohorts
arise from single centers of excellence may indicate that these
studies are less representative of the experiences of patients
undergoing IPAA in the general population. Our study evalu-
ated the experiences of patients with IPAA across practice
settings, including both university hospitals and community
practices. Although there was no significant difference when
evaluating a history of pouch-related symptoms among patients
seen in differing practice settings, we view the ability to
evaluate patients across a more broad geographic area and
multiple practice settings as a strength.
Our study has limitations as well. Although a subset of the
CCFA Partners cohort has been validated for factors such as
disease diagnosis,56 the history of pouchitis symptoms and IPAA
surgery for this study are self-reported. The inability to validate
patient-reported pouchitis may have led to a report of pouchitis
when symptoms could have been due to other conditions such as
irritable pouch syndrome or Crohn’s disease of the pouch. Given
our inability to validate the diagnosis of pouchitis, we have used
a more appropriate diagnosis of pouch-related symptoms in our
analyses. As noted previously, the inability to evaluate the rela-
tionship between time since IPAA surgery and the risk of devel-
opment of pouch-related symptoms is a significant limitation.
TABLE 3. Odds of Experiencing Worse Outcomes as
Defined by PROMIS Measures Among Patients from
CCFA Partners with a History of Pouch-Related
Symptoms Within 6 Months of Survey Compared with







Pain interference 4.15 (1.61–10.72) 3.99 (0.153–10.41)
Depression 2.27 (0.92–5.60) 2.07 (0.83–5.16)
Anxiety 2.19 (0.95–5.08) 2.09 (0.90–4.90)
Satisfaction with social role 0.24 (0.09–0.62) 0.24 (0.09–0.63)
Fatigue 4.79 (2.00–11.45) 4.52 (2.88–10.90)
Sleep disturbance 0.82 (0.36–1.83) 0.82 (0.36–1.87)
aFor categorical analysis, PROMIS measures were divided at the point of clinically
meaningful difference (.52 for pain interference, depression, anxiety, and fatigue; ,48
for satisfaction with social role).
bMultivariable analysis adjusted for age and sex.
evaluations where cohorts were followed for up to 15 years after 
IPAA, up to 47% of patients had experienced at least 1 episode of 
pouchitis.3,41,42 Although we were unable to evaluate time since 
IPAA, in our population, 33% of symptomatic pouch patients had 
been diagnosed with UC/IC more than 15 years ago. Additionally, 
the majority of patients who had undergone IPAA and had been 
diagnosed with IBD more than 11 years before completing the 
survey reported at least 1 episode of pouch-related symptoms. 
When evaluating time since diagnosis in this population of pa-
tients with IPAA, a greater proportion of patients had experienced 
pouch-related symptoms at every time point analyzed as com-
pared with those without symptoms.
Early studies indicated that long-term QOL after ileal 
pouch surgery was excellent,43 with similar cohorts demonstrat-
ing good QOL compared with the general population44–47 
despite the initial surgery-specific complications in some 
cases.48 Improvements in QOL have been noted as early as 1 
month after ileostomy.49 However, other studies have demon-
strated decreased QOL and functional outcomes among patients 
undergoing IPAA when compared with the general popula-
tion,50 whereas another study noted no major improvement in 
QOL after IPAA.51 When QOL has been examined more spe-
cifically among patients with a history of pouchitis, the effects 
on QOL seem more significant. A history of pouchitis has been 
associated with negative effects on multiple QOL scales,52 and 
patients experiencing chronic pouchitis have demonstrated 
decreased QOL and satisfaction with surgery.53
Although the PROMIS measures have been validated 
among patients with IBD, another key advantage of evaluating 
QOL with the PROMIS measures is the ability to compare 
with the general population. We found that patients with
Although we demonstrated a trend in overall time since IBD
diagnosis, the more clinically meaningful relationship between
time since surgery and symptoms could not be assessed. Despite
nesting this study in a cohort of more than 15,000 participants, the
population reporting a history of restorative proctocolectomy with
IPAA was relatively small. The population of patients without
pouch-related symptoms was even smaller, limiting the number
of variables that we could include in our final multivariable
analyses.
In conclusion, in an analysis of patients with UC or IC who
underwent restorative proctocolectomy with IPAA, those patients
with pouch-related symptoms within the past 6 months demon-
strated significantly worse PROs including pain interference,
depression, satisfaction with social role, and fatigue. Given that
symptomatic pouch patients demonstrated worse PROs, increased
awareness by providers of the impact of pouchitis symptoms on
the QOL of an individual patient appears warranted. In addition to
the standard treatment for pouchitis including antibiotics, symp-
tomatic pouch patients may require alternative treatments target-
ing PROs, such as depression, pain, and social satisfaction.
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